Artrya(ASX) AYA

Market CapA$715.47M

Since IPO (2021)+187%

5 YearN/A

1 Year+110%

1 Month+7%

A$4.35

-0.69%

-0.03Today

Artrya last closing stock price
Metric	Price	Date
Last close	AUD 4.35	2026-09-02

Artrya stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-9%	AUD 4.78	2026-08-26
1 month	+7.41%	AUD 4.05	2026-08-03
3 month	-8.81%	AUD 4.77	2026-06-04
Year to date	-7.64%	AUD 4.71	2025-12-31
1 year	+110.14%	AUD 2.07	2025-09-02
3 year	+1,218.18%	AUD 0.33	2023-08-31
Since inception	+187.21%	AUD 1.53	2021-11-26

Artrya Financials at a Glance

Market Cap

A$715.47M

Revenue (TTM)

A$56.00K

Net Income (TTM)

-A$41.59M

EPS (TTM)

-A$0.17

P/E Ratio

-25.17

Dividend

A$0.00

Beta (Volatility)

-0.24 (Low)

Dividend

A$0.00

Beta (Volatility)

-0.24 (Low)

Price

A$4.35

Volume

Open

A$4.30

Price

A$4.35

Volume

Open

A$4.30

Previous Close

A$4.35

Daily Range

A$4.25 - A$4.44

52-Week Range

A$2.04 - A$6.49

Estimated Earnings Date

Mar 2, 2027

Dividend

A$0.00

Beta (Volatility)

-0.24 (Low)

Price

A$4.35

Volume

Open

A$4.30

Previous Close

A$4.35

Daily Range

A$4.25 - A$4.44

52-Week Range

A$2.04 - A$6.49

Estimated Earnings Date

Mar 2, 2027

AYA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Artrya

Artrya Limited is a medical technology firm specializing in artificial intelligence (AI) to identify individuals at risk of coronary artery disease. The company's flagship product, Salix, is a cloud-based software application that automates the analysis of coronary computed tomography angiography (CCTA) scans.

Products and Services

Salix: AI-driven software for coronary artery disease detection
Cloud-based platform for secure data management
Comprehensive analytics for healthcare providers

Growth Outlook

Strong demand for AI solutions in healthcare is increasing
Partnerships with healthcare institutions are expanding
Focus on enhancing product features to improve user experience

Financial Highlights

Recent quarterly revenue of AUD 14,000, showing potential for growth
Cash and short-term investments total AUD 74.17 million
Current ratio of 15.72 indicates strong liquidity position

Artrya Limited is positioned in a rapidly growing sector, leveraging AI technology to address critical healthcare challenges. The company's innovative approach to coronary artery disease detection through Salix offers significant potential for market penetration. With a solid cash position and a focus on expanding partnerships, Artrya is well-equipped to capitalize on the increasing demand for advanced healthcare solutions. The financial metrics indicate a strong liquidity position, which may support future growth initiatives.

AI Generated • Aug 29, 2026

Industry

Health Care Technology

Sector

Health Care

CEO

John Konstantopoulos

Website

www.artrya.com

Headquarters

West Perth, WA 6005, AU

AYA Financials

Key Financial Metrics (TTM)

Gross Margin

-4382.14%

Operating Margin

-97478.57%

Net Income Margin

-89939.29%

Return on Equity

-30.04%

Return on Capital

-34.75%

Return on Assets

-29.51%

Earnings Yield

-3.97%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$715.47M

Shares Outstanding

163.35M

Volume

Avg. Volume

736.59K

Financials (TTM)

Gross Profit

-A$17.22M

Operating Income

-A$43.91M

EBITDA

-A$41.46M

Operating Cash Flow

-A$30.04M

Capital Expenditure

-A$403.00K

Free Cash Flow

-A$30.45M

Cash & ST Invst.

A$74.17M

Total Debt

A$247.00K

Artrya Performance Analysis

Artrya annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-06-30	AUD 0	N/A
2024	2024-06-30	AUD 0	N/A
2025	2025-06-30	AUD 28,000	N/A
2026	2026-06-30	AUD 28,000	0.0%

Artrya sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-31	N/A
Q4	2025-06-30	15.4%
Q2	2025-12-31	-6.7%
Q4	2026-06-30	N/A

Artrya annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-06-30	AUD -0.14	-45.2%
2024	2024-06-30	AUD -0.18	25.3%
2025	2025-06-30	AUD -0.18	-0.2%
2026	2026-06-30	AUD -0.17	-4.5%

Artrya sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-31	-91100.0%
Q4	2025-06-30	4.6%
Q2	2025-12-31	1.8%
Q4	2026-06-30	-3.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2026YOY CHG

Revenue

A$14.00K

N/A

Gross Profit

-A$618.00K

-6269.2%

Gross Margin

-44.14%

N/A

Market Cap

A$715.47M

N/A

Market Cap/Employee

A$16.64M

N/A

Employees

N/A

Net Income

-A$14.44M

-102.8%

EBITDA

-A$13.81M

-12.9%

Quarterly Fundamentals

Name

Q4 2026YOY CHG

Total Cash

A$74.17M

+918.5%

Total Debt

A$247.00K

-74.0%

Accounts Receivable

A$5.36M

+38.2%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$247.00K

-24.0%

Return on Assets

-29.51%

N/A

Return on Invested Capital

-34.00%

N/A

Free Cash Flow

-A$4.96M

+37.8%

Operating Cash Flow

-A$4.90M

+38.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IMR.AXImricor Medical Systems, Inc.

IMR.AXImricor Medical Systems, Inc.A$1.84-3.67%

CGS.AXCogstate Limited

CGS.AXCogstate LimitedA$3.08+1.32%

PSQ.AXPacific Smiles Group Limited

PSQ.AXPacific Smiles Group LimitedA$2.18+0.00%

AVR.AXAnteris Technologies Ltd

AVR.AXAnteris Technologies LtdA$11.75-1.34%

MYX.AXMayne Pharma Group Limited

MYX.AXMayne Pharma Group LimitedA$3.12-3.41%

OCC.AXOrthocell Limited

OCC.AXOrthocell LimitedA$0.72-2.70%

ONE.AXOneview Healthcare PLC

ONE.AXOneview Healthcare PLCA$0.20+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$224.41+0.03%

PCGPG&E

PCGPG&E$13.33-0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.37+0.00%

NUNu Holdings

NUNu Holdings$15.40+0.07%

ONDSOndas

ONDSOndas$7.61+0.08%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.40+0.00%

INTCIntel

INTCIntel$90.05+0.01%

Questions About AYA

What is the current price of Artrya?

Artrya is trading at A$4.35 per share.

What is the 52-week range for Artrya?

Over the past 52 weeks, Artrya has traded between A$2.04 and A$6.49.

How much debt does Artrya have?

As of the most recent reporting period, Artrya reported total debt of A$247.00K.

How much cash does Artrya have on hand?

Artrya reported A$44.17M in cash and cash equivalents in its most recent financial results.

What is Artrya’s dividend yield?

Artrya does not currently have a dividend yield.

Artrya(ASX) AYA

Artrya Financials at a Glance

AYA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Artrya

AYA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Artrya Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AYA

What is the current price of Artrya?

What is the 52-week range for Artrya?

How much debt does Artrya have?

How much cash does Artrya have on hand?

What is Artrya’s dividend yield?

Premium Investing Services